Last quarter (Q4 2023), VYNE Therapeutics's total revenue was $76.00K, an increase of 1166.67% from the same quarter last year. In Q4, VYNE Therapeutics's net income was $-6.19M. See VYNE Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 424.00K	$ 400.00K	$ 477.00K	$ 931.00K	$ 20.99M	$ 0.00
Cost of Revenue	-	-	-	$ 3.35M	$ 1.39M	-
Gross Profit	$ 400.00K	$ 400.00K	$ 477.00K	$ 931.00K	$ 19.60M	-
Operating Expense	$ 29.68M	$ 29.68M	$ 34.77M	$ 39.84M	$ 133.08M	$ 76.24M
Operating Income	$ -29.26M	$ -29.26M	$ -34.30M	$ -38.91M	$ -113.47M	$ -76.24M
Net Non Operating Interest Income Expense	-	-	-	$ -5.61M	$ -4.39M	$ 2.54M
Other Income Expense	$ -1.39M	$ -1.39M	$ -363.00K	$ 135.00K	$ -137.96M	-
Pretax Income	$ -27.87M	$ -27.87M	$ -33.93M	$ -44.66M	$ -255.83M	$ -73.70M
Tax Provision	$ -123.00K	$ -123.00K	$ 13.00K	$ -448.00K	$ -258.00K	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -28.42M	$ -28.50M	$ -33.95M	$ -44.21M	$ -255.57M	$ -73.70M
Basic EPS	$ -2.78	$ -2.78	$ -7.28	$ -25.64	$ -7.88	$ -12.36
Diluted EPS	$ -2.78	$ -2.78	$ -7.28	$ -25.64	$ -7.88	$ -12.36
Basic Average Shares	$ 41.09M	$ 10.27M	$ 3.19M	$ 2.86M	$ 32.42M	$ 5.95M
Diluted Average Shares	$ 41.09M	$ 10.27M	$ 3.19M	$ 2.86M	$ 32.42M	$ 5.95M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 29.68M	$ 29.68M	$ 34.77M	$ 82.79M	$ 134.47M	$ 76.24M
Net Income From Continuing And Discontinued Operation	$ -28.48M	$ -28.50M	$ -23.21M	$ -44.21M	$ -255.57M	$ -73.70M
Normalized Income	$ -12.73M	-	-	-	$ -116.64M	$ -73.70M
Interest Expense	-	-	-	-	$ 4.39M	-
EBIT	$ -27.83M	$ -27.87M	$ -33.93M	$ -39.05M	$ -251.44M	$ -76.24M
EBITDA	$ -27.71M	$ -28.13M	$ -33.83M	$ -39.05M	$ -251.09M	$ -75.54M

Currency in USD

VYNE Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing